Serum adiponectin, C-peptide and leptin and risk of symptomatic benign prostatic hyperplasia: Results from the prostate cancer prevention trial

Prostate

Volumn 69, Issue 12, 2009, Pages 1303-1311

  Schenk, Jeannette M ^a,b   Kristal, Alan R ^a,b   Neuhouser, Marian L ^a   Tangen, Catherine M ^a   White, Emily ^a,b   Lin, Daniel W ^a,c   Thompson, Ian M ^d  

^a USA   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d University of Texas Health Science Center   (United States)

Author keywords

Benign prostatic hyperplasia; Insulin resistance; Lower urinary tract symptoms; Obesity

Indexed keywords

ADIPONECTIN; C PEPTIDE; FINASTERIDE; LEPTIN;

ADULT; AGED; ARTICLE; CANCER PREVENTION; CANCER RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; INSULIN RELEASE; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; MALE; OBESITY; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM;

ADIPONECTIN; AGED; C-PEPTIDE; CASE-CONTROL STUDIES; DISEASE PROGRESSION; HUMANS; INSULIN RESISTANCE; LEPTIN; MALE; MIDDLE AGED; OBESITY; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; RISK FACTORS; WASHINGTON;

EID: 67650888910     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20974     Document Type: Article

References (35)

1. Kirby RS. The natural history of benign prostatic hyperplasia: What have we learned in the last decade? Urology 2000;56:3-6.
2. Platz EA, Smit E, Curhan GC, Nyberg LM, Giovannucci EL. Prevalence of and racial/ethnic variation in lower urinary tract symptoms and noncancer prostate surgery in U.S. men. Urology 2002;59:877-883.
3. Kristal AR, Arnold KB, Schenk JM, Neuhouser ML, Weiss N, Goodman PJ, Antvelink CM, Penson DF, Thompson IM. Race/ ethnicity, obesity, health related behaviors and the risk of symptomatic benign prostatic hyperplasia: Results from the Prostate Cancer Prevention Trial. J Urol 2007;177:1395-1400.
4. Giovannucci E, Rimm EB, Chute CG, Kawachi I, Colditz GA, Stampfer MJ, Willett WC. Obesity and benign prostatic hyperplasia. Am J Epidemiol 1994;140:989-1002.
5. Dahle SE, Chokkalingam AP, Gao YT, Deng J, Stanczyk FZ, Hsing AW. Body size and serum levels of insulin and leptin in relation to the risk of benign prostatic hyperplasia. J Urol 2002; 168:599-604.
6. Haque WA, Garg A. Adipocyte biology and adipocytokines. Clin Lab Med 2004;24(1):217-234.
7. Yalow RS, Glick SM, Roth J, Berson SA. Plasma insulin and growth hormone levels in obesity and diabetes. Ann NY Acad Sci 1965;131:357-373.
8. Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR, Ohannesian JP, Marco CC, McKee LJ, Bauer TL, et al. Serum immunoreactive-leptin concentrations in normalweight and obese humans. N Engl J Med 1996;334(5):292-295.
9. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K, Shimomura I, Nakamura T, Miyaoka K, Kuriyama H, Nishida M, Yamashita S, Okubo K, Matsubara K, Muraguchi M, Ohmoto Y, Funahashi T, Matsuzawa Y. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999;257:79-83.
10. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, Lieber MM, Cespedes RD, Atkins JN, Lippman SM, Carlin SM, Rayan A, Szczepanek CM, Crowley JJ, Coltman CA. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349:215-224.
11. Neuhouser ML, Schenk JM, Song YJ, Tangen CM, Goodman PJ, Pollak M, Penson DF, Thompson IM, Kristal AR. Insulin-like growth factor-1, insulin-like growth factor binding protein-3 and risk of benign prostate hyperplasia in the Prostate Cancer Prevention Trial. Prostate 2008;68:1477-1486.
12. Kristal AR, Schenk JM, Song YJ, Arnold KB, Neuhouser ML, Goodman PJ, Lin D, Stanczyk F, Thompson IM. Serum steroid and sex hormone binding globulin concentrations and the risk of incident benign prostatic hyperplasia (BPH): Results from the Prostate Cancer Prevention Trial. Am J Epidemiol 2008;168:1416-1424.
13. Kristal AR, Arnold KB, Schenk JM, Neuhouser ML, Goodman PJ, Penson DF, Thompson IM. Dietary patterns, supplement use and risk of symptomatic benign prostatic hyperplasia (BPH): Results from the Prostate Cancer Prevention Trial. Am J Epidemiol 2008;167:925-934.
14. Breslow NE, Day NE. Statistical methods in cancer research. Vol 1: The analysis of case-control studies. Davis W, editor. Classical methods of analysis of grouped data Lyon: Intl Agency for Research on Cancer; 1980.
15. Lagiou P, Signorello LB, Trichopoulos D, Tzonou A, Trichopoulou A, Mantzoros CS. Leptin in relation to prostate cancer and benign prostatic hyperplasia. Int J Cancer 1998;76:25-28.
16. Nandeesha H, Koner BC, Dorairajan LN, Sen SK. Hyper-insulinemia and, dyslipidemia in non-diabetic benign prostatic hyperplasia. Clinica Chimica Acta 2006;370(1-2):89-93.
17. Michalakis K, Williams CJ, Mitsiades N, Blakeman J, Balafouta-Tselenis S, Giannopoulous A, Mantzoros CS. Serum adiponectin concentrations and tissue expression of adiponectin receptors are reduced in patients with prostate cancer: A case control study. Cancer Epidemiol Biomarkers Prev 2007;16(2):308-313.
18. Gotkas S, Yilmaz MI, Caglar K, Sonmez A, Kilic S, Bedir S. Prostate cancer and adiponectin. Urology 2005;65:1168-1172.
19. Parsons JK, Carter HB, Partin AW, Windham BG, Metter EJ, Ferrucci L, Landis P, Platz EA. Metabolic factors associated with benign prostatic hyperplasia. J Clin Endocrinol Metab 2006; 91(7):2562-2568.
20. Kelesidis I, Kelesidis T, Mantzoros CS. Adiponectin and cancer: A systematic review. Br J Cancer 2006;94:1221-1225.
21. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, Yamashita S, Noda M, Kita S, Ueki K, Eto K, Akanuma Y, Froguel P, Foufelle F, Ferre P, Carling D, Kimura S, Nagai R, Kahn BB, Kadowaki T. Adiponectin stimulates glucose utilization and fatt-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002;8(11):1288-1295.
22. Mistry T, Digby JE, Chen J, Desai KM, Randeva HS. The regulation of adiponectin receptors in human prostate cancer cell lines. Biochem Biophys Res Commun 2006;348:832-838.
23. Bub JD, Myiyazaki T, Iwamoto Y. Adiponectin as a growth inhibitor in prostate cancer cells. Biochem Biophys Res Commun 2006;340:1158-1166.
24. Combs T, Berg A, Obicim S, Scherer PE, Rossetti L. Endogenous glucose production is inhibited by the adipose-derived protein Acrp30. J Clin Invest 2001;108:1875-1881.
25. Berg AH, Combs TP, Du X, Brownlee M, Scherer PE. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 2001;7(8):947-953.
26. Duncan BB, Schmidt MI, Pankow JS, Bang H, Couper D, Ballantyne CM, Hoogeveen RC, Heiss G. Adiponectin and the development of type 2 diabetes. The Atherosclerosis Risk in Communities Study. Diabetes 2004;53:2473-2478.
27. Lu JY, Huang KC, Chang LC, Huang YS, Chi YC, Su TC, Chen CL, Yang WS. Adiponectin: A biomarker of obesity-induced insulin resistance in adipose tissue and beyond. J Biomed Sci 2008;15(5):565-576.
28. Ryo M, Nakamura T, Kihara S, Kumada M, Shibazaki S, Takahashi M, Nagai M, Matsuzawa Y, Funahashi T. Adiponectin as a biomarker of the metabolic syndrome. Circ J 2004;68:975-981.
29. Rohrmann S, Smit E, Giovannucci E, Platz EA. Association between markers of the metabolic syndrome and lower urinary tract symptoms in the Third National Health and Nutrition Examination Survey (NHANES III). Int J Obes 2005;29:310-316.
30. Hovorka R, Jones RH. How to measure insulin secretion. Diabetes Metab Rev 1994;10(2):91-117.
31. Richter EA, Mikines KJ, Galbo J, Kiens B. Effect of exercise on insulin action in human skeletal muscle. J Appl Physiol 1989;66:876-885.
32. Blüher M, Bullen JW, Lee JH, Kralisch S, Fasshauer M, Klöting N, Niebauer J, Schön MR, Williams CJ, Mantzoros CS. Circulating adiponectin and expression of adiponectin receptors in human skeletal muscle: Associations with metabolic parameters and insulin resistance and regulation by physical training. J Clin Endocrinol Metab 2006;91:2310-2316.
33. Barry MJ, Cockett AT, Holtgrewe HL, McConnell JD, Sihelnik SA, Winfield HN. Relationship of symptoms of prostatatism to commonly used physiological and anatomical measures of the severity of benign prostatic hyperplasia. J Urol 1993;150:351-358.
34. Abrams P, D'Ancona C, Griffiths D, van Kerrebroeck P, Nishizawa O, Nitti V, Keong Tatt F, Tubaro A, Wein A, Belal M. Lower urinary tract symptom: Etiology, patient assessment and predicting outcome from therapy. In: McConnell J, Abrams P, Denis L, Khoury S, Roehrborn C, editors. Male lower urinary tract dysfunction-Evaluation and management. Paris: Health Publications; 2005. pp. 69-142.
35. Gades NM, Jacobsen DJ, Girman CJ, Roberts RO, Lieber MM, Jacobsen SJ. Prevalence of conditions potentially associated with lower urinary tract symptoms in men. Br J Urol 2004;95(4):549-553.